These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

411 related items for PubMed ID: 15786022

  • 1. Concepts in radiotherapy and immunotherapy: anti-CD20 mechanisms of action and targets.
    Maloney DG.
    Semin Oncol; 2005 Feb; 32(1 Suppl 1):S19-26. PubMed ID: 15786022
    [Abstract] [Full Text] [Related]

  • 2. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance.
    Smith MR.
    Oncogene; 2003 Oct 20; 22(47):7359-68. PubMed ID: 14576843
    [Abstract] [Full Text] [Related]

  • 3. Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma.
    Grillo-López AJ, White CA, Varns C, Shen D, Wei A, McClure A, Dallaire BK.
    Semin Oncol; 1999 Oct 20; 26(5 Suppl 14):66-73. PubMed ID: 10561020
    [Abstract] [Full Text] [Related]

  • 4. Novel anti-CD20 antibody TGLA with enhanced antibody-dependent cell-mediated cytotoxicity mediates potent anti-lymphoma activity.
    Lv M, Lin Z, Qiao C, Gen S, Lang X, Li Y, Feng J, Shen B.
    Cancer Lett; 2010 Aug 01; 294(1):66-73. PubMed ID: 20202740
    [Abstract] [Full Text] [Related]

  • 5. Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies.
    Treon SP, Mitsiades C, Mitsiades N, Young G, Doss D, Schlossman R, Anderson KC.
    J Immunother; 2001 Aug 01; 24(3):263-71. PubMed ID: 11394505
    [Abstract] [Full Text] [Related]

  • 6. Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity.
    van Meerten T, van Rijn RS, Hol S, Hagenbeek A, Ebeling SB.
    Clin Cancer Res; 2006 Jul 01; 12(13):4027-35. PubMed ID: 16818702
    [Abstract] [Full Text] [Related]

  • 7. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.
    Jazirehi AR, Bonavida B.
    Oncogene; 2005 Mar 24; 24(13):2121-43. PubMed ID: 15789036
    [Abstract] [Full Text] [Related]

  • 8. T cells armed with anti-CD3 x anti-CD20 bispecific antibody enhance killing of CD20+ malignant B cells and bypass complement-mediated rituximab resistance in vitro.
    Gall JM, Davol PA, Grabert RC, Deaver M, Lum LG.
    Exp Hematol; 2005 Apr 24; 33(4):452-9. PubMed ID: 15781336
    [Abstract] [Full Text] [Related]

  • 9. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression.
    Davis TA, Czerwinski DK, Levy R.
    Clin Cancer Res; 1999 Mar 24; 5(3):611-5. PubMed ID: 10100713
    [Abstract] [Full Text] [Related]

  • 10. The role of complement in the mechanism of action of rituximab for B-cell lymphoma: implications for therapy.
    Zhou X, Hu W, Qin X.
    Oncologist; 2008 Sep 24; 13(9):954-66. PubMed ID: 18779537
    [Abstract] [Full Text] [Related]

  • 11. Mechanism of action of rituximab.
    Maloney DG.
    Anticancer Drugs; 2001 Jun 24; 12 Suppl 2():S1-4. PubMed ID: 11508930
    [Abstract] [Full Text] [Related]

  • 12. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
    Marcus R, Hagenbeek A.
    Eur J Haematol Suppl; 2007 Jan 24; (67):5-14. PubMed ID: 17206982
    [Abstract] [Full Text] [Related]

  • 13. Intratumoral but not systemic delivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B cell lymphoma.
    Betting DJ, Yamada RE, Kafi K, Said J, van Rooijen N, Timmerman JM.
    J Immunother; 2009 Jan 24; 32(6):622-31. PubMed ID: 19483647
    [Abstract] [Full Text] [Related]

  • 14. The anti-CD20 antibody rituximab augments the immunospecific therapeutic effectiveness of an anti-CD19 immunotoxin directed against human B-cell lymphoma.
    Flavell DJ, Warnes SL, Bryson CJ, Field SA, Noss AL, Packham G, Flavell SU.
    Br J Haematol; 2006 Jul 24; 134(2):157-70. PubMed ID: 16771848
    [Abstract] [Full Text] [Related]

  • 15. Inhibition of human B-cell lymphoma by an anti-CD20 antibody and its chimeric F(ab')2 fragment via induction of apoptosis.
    Liu Y, Zheng M, Lai Z, Xiong D, Fan D, Xu Y, Peng H, Shao X, Xu Y, Yang M, Wang J, Liu H, Xie Y, Yang C, Zhu Z.
    Cancer Lett; 2004 Mar 18; 205(2):143-53. PubMed ID: 15036646
    [Abstract] [Full Text] [Related]

  • 16. [Monoclonal antibody therapy for malignant lymphoma].
    Buske C, Dreyling M, Unterhalt M, Hiddemann W.
    Med Klin (Munich); 2005 Jan 15; 100(1):14-24. PubMed ID: 15654538
    [Abstract] [Full Text] [Related]

  • 17. Characterization of novel murine anti-CD20 monoclonal antibodies and their comparison to 2B8 and c2B8 (rituximab).
    Nishida M, Usuda S, Okabe M, Miyakoda H, Komatsu M, Hanaoka H, Teshigawara K, Niwa O.
    Int J Oncol; 2007 Jul 15; 31(1):29-40. PubMed ID: 17549402
    [Abstract] [Full Text] [Related]

  • 18. Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugates.
    Law CL, Cerveny CG, Gordon KA, Klussman K, Mixan BJ, Chace DF, Meyer DL, Doronina SO, Siegall CB, Francisco JA, Senter PD, Wahl AF.
    Clin Cancer Res; 2004 Dec 01; 10(23):7842-51. PubMed ID: 15585616
    [Abstract] [Full Text] [Related]

  • 19. Rituximab-mediated cell signaling and chemo/immuno-sensitization of drug-resistant B-NHL is independent of its Fc functions.
    Vega MI, Huerta-Yepez S, Martinez-Paniagua M, Martinez-Miguel B, Hernandez-Pando R, González-Bonilla CR, Chinn P, Hanna N, Hariharan K, Jazirehi AR, Bonavida B.
    Clin Cancer Res; 2009 Nov 01; 15(21):6582-94. PubMed ID: 19861448
    [Abstract] [Full Text] [Related]

  • 20. lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells.
    Wu L, Adams M, Carter T, Chen R, Muller G, Stirling D, Schafer P, Bartlett JB.
    Clin Cancer Res; 2008 Jul 15; 14(14):4650-7. PubMed ID: 18628480
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.